Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), recently sold a substantial block of the company's ordinary shares. The ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...

Teva Pharmaceutical Industries Ltd is a global leader in the pharmaceutical industry, specializing in the development, manufacture, and distribution of generic and specialty medicines, as well as ...

The most notable increase was Teva Pharmaceutical Industries Ltd (NYSE:TEVA), with an additional 7,569,450 shares, bringing the total to 8,997,400 shares. This adjustment represents a significant 530.

When Investors Make Decisions in Teva Pharmaceutical Industries Limited American Depositary Shares TEVA Opportunities Surface ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Teva, a global pharmaceutical leader, to install the SaverOne System across its entire fleet of 50 delivery trucks in IsraelPetah Tikvah, Israel, ...

What do the analysts say? Following the release of the quarterly report, Bank of America cut its price target for Teva from $26 to $23, a price that represents a 29.7% premium on the price in New York ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...